Primary Open Angle Glaucoma- Pipeline Insight, 2024

Primary Open Angle Glaucoma- Pipeline Insight, 2024

DelveInsight’s, “Primary Open Angle Glaucoma- Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Primary Open Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Primary Open Angle Glaucoma: Understanding

Primary Open Angle Glaucoma: Overview

Primary open-angle glaucoma is a syndrome of optic nerve damage associated with an open anterior chamber angle and an elevated or sometimes average intraocular pressure (IOP). Primary open-angle glaucoma includes both adult-onset disease (occurring after 40 years of age) and juvenile-onset disease (occurring between the ages of 3 and 40 years of age).Primary open-angle glaucoma occurs due to a deeper issue that impacts the eye’s natural drainage system. The eye’s drainage system works like a sink. If a blockage develops, or if fluid is produced faster than it can escape, an overflow will occur. In the eye, this overflow causes the pressure to elevate. The optic nerve is the structure most vulnerable to damage from elevated pressure. Continuous elevated pressure or spikes in pressure, can damage the optic nerve. If left untreated, glaucoma can lead to blindness which is irreversible.

The vast majority of cases of primary open-angle glaucoma, patients are asymptomatic. Because initial visual loss is to peripheral vision and the field of vision is covered by the other eye, patients do not notice visual loss until severe and permanent damage has occurred, often impacting on central (foveal) vision. By then, up to 90% of the optic nerve fibres may have been irreversibly damaged. Among patients with an elevated intraocular pressure, a relatively thin central cornea is major risk factor for the disease. Evidence for other risk factors (diabetes mellitus, elevated systolic blood pressure, and migraine, among others) is less consistent.

Risk factors for primary open-angle glaucoma include:

• Older age
• Positive family history
• African ethnicity
• Thinner central corneal thickness
• Systemic hypertension
• Diabetes
• Myopia

Diagnosis is by ophthalmoscopy, gonioscopy, visual field examination, and measurement of central corneal thickness and IOP. Diagnosis of primary open-angle glaucoma is suggested by the examination, but similar findings can result from other optic neuropathies (eg, caused by ischemia, cytomegalovirus infection, or vitamin B12 deficiency). Vision loss from POAG is irreversible. Management is, therefore, aimed at slowing the progression of the disease, thereby maintaining optimum visual function.

The only proven treatment for POAG is lowering IOP. IOP may be lowered by medical therapy (topical and systemic), laser therapy and surgical procedures. It includes topical drugs (eg, prostaglandin analogs, beta-blockers) and often requires laser or incisional surgery to increase aqueous drainage.

""Primary Open Angle Glaucoma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Open Angle Glaucoma pipeline landscape is provided which includes the disease overview and Primary Open Angle Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Primary Open Angle Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Open Angle Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Primary Open Angle Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve

Primary Open Angle Glaucoma.

Primary Open Angle Glaucoma Emerging Drugs Chapters

This segment of the Primary Open Angle Glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary Open Angle Glaucoma Emerging Drugs

• STN1012600: Santen Pharmaceutical Co., Ltd.

It is a prostaglandin analogue eye drop drug product with a novel mode of action that is a dual agonist for both FP and EP3 receptors for the treatment of glaucoma and ocular hypertension. The investigational therapy completed an additional Phase II in December 2021 in the U.S. and started Phase III trial in August 2022 in Japan for patients with Primary Open Angle Glaucoma and Ocular Hypertension.

• TO-O-1001: TheratOcular Biotek Co., Ltd.

TO-O-1001 (Formerly known as MG-O-1001) eye drops is a patented new generation Rho kinase (ROCK) inhibitor for treating patients with primary open-angle glaucoma or ocular hypertension. Its therapeutic potency is established through a dual-targeting mechanism, which in turn leads to relaxation of the cells of trabecular meshwork and the inner walls of Schlemm’s canal. The combined results are increase of aqueous humor outflow, so to achieve the intraocular pressure lowering effect.

It was selected for features that include novel and proven working mechanism, best in class as the ROCK inhibition, and user-friendly as it is taken once a day. It is currently being investigated in Phase I/II trial to demonstrate the product’s safety, tolerability and efficacy for POAG.

Further product details are provided in the report……..

Primary Open Angle Glaucoma: Therapeutic Assessment

This segment of the report provides insights about the different Primary Open Angle Glaucoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Primary Open Angle Glaucoma

There are approx. 8+ key companies which are developing the therapies for Primary Open Angle Glaucoma. The companies which have their Primary Open Angle Glaucoma drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Primary Open Angle Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary Open Angle Glaucoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Open Angle Glaucoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Open Angle Glaucoma drugs.

Primary Open Angle Glaucoma Report Insights

• Primary Open Angle Glaucoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Primary Open Angle Glaucoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Primary Open Angle Glaucoma drugs?
• How many Primary Open Angle Glaucoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Open Angle Glaucoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary Open Angle Glaucoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Primary Open Angle Glaucoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Santen Pharmaceutical Co., Ltd.
• PH PHARMA CO. LTD.
• Whitecap Biosciences, LLC
• Ocular Therapeutix, Inc.
• TheratOcular Biotek Co., Ltd.

Key Products

• STN1012600
• PHP-201
• WB007
• OTX-TIC
• TO-O-1001